Growth Hormone Research Peptides Guide
Overview
This guide covers 3 research peptides in the Growth Hormone category. Each compound is evaluated on its evidence base, mechanism, safety profile, and current clinical status.
HGH 191AA — FDA Approved
Evidence: A | Status: FDA-approved (multiple indications). Numerous brand-name products available worldwide.
HGH 191AA refers to recombinant human growth hormone (somatropin) — a 191-amino acid, single-chain polypeptide (MW ~22,124 g/mol) identical in sequence to endogenous pituitary growth hormone.
Use cases: Anti-Aging & Longevity, Body Composition
Somatropin (rHGH) — FDA-Approved
Evidence: A | Status: FDA-approved for multiple indications. Extensive clinical data spanning decades.
Somatropin is recombinant human growth hormone (rHGH), a 191-amino-acid protein identical to naturally produced pituitary GH. Unlike secretagogues (which stimulate GH release), somatropin IS the direct hormone.
Use cases: Growth hormone deficiency, Turner syndrome, Anti-aging (off-label), Body composition
CJC-1295 with DAC — Phase I-II data; research compound
Evidence: C | Status: Research compound. Phase 1/2 clinical data exists (ConjuChem). Not approved for any indication.
CJC-1295 with DAC (Drug Affinity Complex) is a modified growth hormone-releasing hormone (GHRH) analog with a unique lysine-linked maleimidopropionic acid moiety that covalently binds to circulating albumin in vivo.
Use cases: Growth Hormone, Body Composition, Recovery
Related Products
CJC-1295 DAC 5mg
5mg